INLIF LIMITED Announces Pricing of $3.75 Million Registered Direct Offering

The financing includes multiple warrant series, with downward exercise-price resets and price-based additional share issuance.

Rhea-AI Summary

INLIF (Nasdaq: INLF) entered into securities purchase agreements with institutional investors for a registered direct offering expected to raise approximately US$3.75 million.

The offering includes 435,000 Class A ordinary shares and pre-funded warrants for up to 1,908,750 shares, each accompanied by Series A, B and C warrants. Combined prices are US$1.60 per share package and US$1.5999 per pre-funded warrant package. Gross proceeds exclude placement agent fees and other offering expenses. INLIF expects closing on or about October 20, 2026, subject to customary closing conditions.

Series A and B warrants initially cover up to 2,343,750 shares and 2,343,750 units, respectively. Both have a one-time downward exercise-price reset on the twentieth trading day after closing. Series C warrants provide additional shares determined by a price-based adjustment over the first ten trading days beginning on issuance.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Registered direct offering is expected to raise approximately US$3.75 million in gross proceeds. 1.3× market cap

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.435,000 new Class A shares at US$1.60 per accompanying warrant package dilute existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants cover up to 1,908,750 shares, priced at US$1.5999 per package plus US$0.0001 exercise.
• Minor point. Forward-looking: it has not happened yet and may not happen.Series A warrants initially cover up to 2,343,750 shares at US$1.60, exercisable immediately through five years after closing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Series B warrants initially cover up to 2,343,750 units at US$1.60, exercisable immediately through 60 days after issuance.
• Minor point. Forward-looking: it has not happened yet and may not happen.Series A and B exercise prices face a one-time downward reset on the twentieth trading day after closing.

2 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.Series C warrants add shares at US$0.0001 each, determined by a price-based adjustment over ten trading days beginning on issuance.
• Minor point. Forward-looking: it has not happened yet and may not happen.Placement agent fees and other offering expenses will reduce proceeds available to INLIF.

News Explained

The offering is priced but not closed; Series A and B warrants are immediately exercisable at US$1.60, expiring five years after closing and 60 days after issuance, respectively, while Series C is exercisable at US$0.0001 for an adjustment-based number of shares, which could dilute existing holders if exercised.

Argus 15 min delay 69 alerts

-85.88% vs previous close $0.36 last price 164.3x rel. volume Open Argus

Details

Market move: INLF -85.88% vs previous close. registered direct offering

-34.0% Trough in 7 min

$0.36 – $2.60 Day Range

$392,616 Mkt Cap at Last Price

On Oct 19, the day this news came out, the latest delayed price for INLF is 85.88% below the previous close. Argus tracked a trough of -34.0% from its starting point during tracking. Our momentum scanner has recorded 69 alerts for this stock so far that day. The latest delayed price is $0.36. Relative volume is exceptionally heavy at 164.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: $3.75 million Ordinary shares offered: 435,000 shares Pre-funded warrants: Up to 1,908,750 shares +5 more

Expected gross proceeds

$3.75 million

Before placement agent fees and other offering expenses

Ordinary shares offered

435,000 shares

Class A ordinary shares

Pre-funded warrants

Up to 1,908,750 shares

Warrants included in the offering

Package purchase prices

$1.60 per ordinary share package; $1.5999 per pre-funded warrant package

Each package includes accompanying ordinary warrants

Series A warrants

Up to 2,343,750 shares

Initial underlying share amount

Series B warrants

Up to 2,343,750 units

Initial underlying unit amount

Series A warrant exercise terms

$1.60 per share; expires five years after closing

Immediately exercisable

Series B warrant exercise terms

$1.60 per unit; expires 60 days after issuance

Immediately exercisable

Key Terms

registered direct offering, pre-funded warrants, form f-3, prospectus supplement

4 terms

registered direct offering financial

"in a registered direct offering (the “Offering”)"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"pre-funded warrants to purchase up to 1,908,750 Ordinary Shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

form f-3 regulatory

"registration statement on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"A prospectus supplement relating to the securities"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Quanzhou, China, Oct. 19, 2026 (GLOBE NEWSWIRE) -- INLIF LIMITED (Nasdaq: INLF) (together with all its subsidiaries and consolidated entities, the "Company" or "INLIF"), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of an aggregate of 435,000 Class A Ordinary Shares, par value of US$0.0001 per share, of the Company (the “Ordinary Shares”), pre-funded warrants to purchase up to 1,908,750 Ordinary Shares (the “Pre-Funded Warrants”), Series A warrants to initially purchase up to 2,343,750 Ordinary Shares (the “Series A Warrants”), Series B warrants to initially purchase up to 2,343,750 units (the “Series B Warrants”, each unit consisting of one Ordinary Share, or one Pre-Funded Warrant in lieu thereof and one Series A Warrant ), and Series C warrants to purchase a number of Ordinary Shares to be determined in accordance with their terms (the “Series C Warrants” and, together with the Series A Warrants and the Series B Warrants, the “Ordinary Warrants”), in a registered direct offering (the “Offering”). Each Ordinary Share or Pre-Funded Warrant will be sold together with one accompanying Series A Warrant, one accompanying Series B Warrant and one accompanying Series C Warrant at a combined purchase price of US$1.60 per Ordinary Share and accompanying Ordinary Warrants, or US$1.5999 per Pre-Funded Warrant and accompanying Ordinary Warrants, which equals the combined purchase price per Ordinary Share and accompanying Ordinary Warrants minus US$0.0001, the exercise price of each Pre-Funded Warrant. The aggregate gross proceeds from the Offering are expected to be approximately US$3.75 million, prior to deducting placement agent fees, legal fees, administrative and other offering-related expenses.

The Series A Warrants will be immediately exercisable at US$1.60 per Ordinary Share and expire five years after closing. The Series B Warrants will be immediately exercisable at US$1.60 per unit and expire 60 days after issuance. Each of the Series A Warrants and Series B Warrants is subject to a one-time downward exercise price reset on the twentieth trading day after closing along with other adjustments therein. The Series C Warrants will be exercisable at US$0.0001 per share for additional Ordinary Shares determined by a price-based adjustment over the first ten trading days beginning on issuance.

The transaction is expected to close on or about October 20, 2026, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent for the offering. Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Pryor Cashman LLP is acting as U.S. securities counsel to the placement agent, in connection with the Offering.

The registered direct offering is being made pursuant to the Company’s registration statement on Form F-3 (File No. 333-292580) previously filed with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective by the SEC on January 12, 2026. A prospectus supplement relating to the securities will be filed by the Company with the SEC. All information filed with the SEC can be obtained over the internet on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745 or by email at syndicate@maximgrp.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About INLIF LIMITED

INLIF is a holding company and an exempted company incorporated in the Cayman Islands with limited liability. Through its operating entity in the People's Republic of China, Ewatt Robot Equipment Co. Ltd., established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. It is also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms, all developed by itself. It has also built experience in industrial automation solutions, including in the new energy sector, as well as intelligent robotics in recent years. For more information, please visit the Company's website: https://ir.yiwate88.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.  

These forward-looking statements are subject to substantial risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied, including without limitation: the Company’s ability to complete the Offering in accordance with the expected timeline and terms; satisfaction of closing conditions; the planned use and actual deployment of net proceeds; adverse changes in global market conditions and capital market sentiment; risks relating to the Company’s business strategy adjustment and asset optimization;  the ability to maintain the Company’s Nasdaq listing status; changes in industry policies and regulatory rules; future capital financing needs; and other risk factors disclosed in the Company’s periodic filings and subsequent submissions with the SEC, including its Annual Report on Form 20-F.  

Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission. 

Contact

INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does INLIF expect to raise in its registered direct offering, and at what price?

INLIF expects approximately US$3.75 million in gross proceeds, before placement agent fees and other offering expenses. Each ordinary share with accompanying Series A, B and C warrants costs US$1.60; each pre-funded warrant with those accompanying warrants costs US$1.5999, with a US$0.0001 exercise price.

When is INLIF's registered direct offering expected to close?

INLIF expects the offering to close on or about October 20, 2026, subject to satisfaction of customary closing conditions.

What does a unit under INLIF's Series B warrants contain?

Each Series B warrant unit consists of one ordinary share and one Series A warrant, with a pre-funded warrant permitted in place of the ordinary share.